75 -5 (79) 2025 - Khayitov D.Kh. - OPTIMIZATION OF THE EFFECTIVENESS OF ANTIPLATELET THERAPY AFTER CORONARY ARTERY STENTING IN ACUTE MYOCARDIAL INFARCTION

OPTIMIZATION OF THE EFFECTIVENESS OF ANTIPLATELET THERAPY AFTER CORONARY ARTERY STENTING IN ACUTE MYOCARDIAL INFARCTION

Khayitov D.Kh. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Resume

Recent studies confirm the effectiveness of an individualized approach to antiplatelet therapy after coronary artery stenting in patients with acute myocardial infarction, particularly in those at high bleeding risk. A randomized trial [1] demonstrated that shortening the course of dual antiplatelet therapy (DAPT) to one month followed by P2Y₁₂ inhibitor monotherapy does not increase ischemic events but significantly reduces bleeding risk. Similar findings were confirmed by the SHARP-MI registry [2], where early discontinuation of DAPT (after ≥1 month) showed comparable clinical effectiveness to standard-duration therapy. Additionally, another study [3] showed that switching to prosugrel monotherapy three months after PCI reduces the rates of major bleeding and overall complications. These findings support the rationale for a personalized and adaptive DAPT strategy to optimize the balance between thrombotic and hemorrhagic risks

Keywords: acute myocardial infarction, dual antiplatelet therapy, coronary artery stenting, bleeding risk, P2Y₁₂ inhibitors, prasugrel

First page

384

Last page

387

For citation:Khayitov D.Kh. - OPTIMIZATION OF THE EFFECTIVENESS OF ANTIPLATELET THERAPY AFTER CORONARY ARTERY STENTING IN ACUTE MYOCARDIAL INFARCTION//New Day in Medicine 5(79)2025 384-387 https://newdayworldmedicine.com/en/new_day_medicine/5-79-2025

List of References

1. Smits PC et al., «Abbreviated Antiplatelet Therapy after Coronary Stenting in Patients with Myocardial Infarction at High Bleeding Risk», стр. 1220–1237, 2022.
2. Hakansson A et al., «Abbreviated Versus Standard Dual Antiplatelet Therapy Times after PCI in Patients with High Bleeding Risk with Acute Coronary Syndrome», стр. e034709, 2024.
3. Lee Y‑J et al., «Ticagrelor Monotherapy After 3-Month Dual Antiplatelet Therapy in Acute Coronary Syndrome by High Bleeding Risk», стр. 324–337, 2022.
4. An J., «Shortening the Duration of Dual Antiplatelet Therapy in Patients with Acute Coronary Syndrome Undergoing PCI», стр. 101–114, 2022.
5. Sibbing D. et al., «Guided De-Escalation of Antiplatelet Treatment in Patients With Acute Coronary Syndrome Undergoing PCI (TROPICAL-ACS)», стр. 1747–1757, 2017
6. Mehran R. et al., «Ticagrelor with or without Aspirin in High-Risk Patients After PCI (TWILIGHT)», стр. 2032–2042, 2019.

   file

   download